Clinical Trial Update: Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Inaxaplin for APOL1-associated proteinuric kidney disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apol1-associated Nephropathy

Drugs mentioned

• Inaxaplin (inaxaplin)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Proteinuric Kidney Disease | Phase 2 | Status: RECRUITING